Insulin-resistant high blood sugar — the condition GLP-1 medicines were built for.
Type 2 diabetes is the headline use case for GLP-1 receptor agonists, which combine glycemic control with weight loss and, for several agents, proven cardiovascular benefit. Semaglutide and tirzepatide are the most prominent, with metformin remaining the long-standing first-line oral agent.
This is a managed medical condition. Everything here is educational context for a conversation with a clinician — these are prescription medicines requiring monitoring, not a self-treatment menu.
Ranked by editorial relevance — a measure of how central each compound is to the conversation, not a claim of effectiveness.
| Compound | Type | Why it's relevant |
|---|---|---|
| Semaglutide | peptide | GLP-1 agonist; glycemic control + CV-outcomes data. |
| Tirzepatide | peptide | Dual GIP/GLP-1; strong glycemic + weight effect. |
| Metformin | supplement | Long-standing first-line oral agent. |
| Berberine | supplement | Supplement with glycemic-marker interest. |